Biogen Inc. Common Stock (BIIB)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Biogen Inc. Common Stock (BIIB)
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Key Insights
Critical company metrics and information
Share Price
$160.51Market Cap
$23.39 BillionTotal Outstanding Shares
145.72 Million SharesTotal Employees
7,570Dividend
No dividendIPO Date
September 17, 1991SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.biogen.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $2.13 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-1.34 Billion |
| Net Cash Flow, Continuing | $-643.30 Million |
| Net Cash Flow From Investing Activities, Continuing | $-1.43 Billion |
| Net Cash Flow From Financing Activities | $-1.34 Billion |
| Net Cash Flow From Operating Activities, Continuing | $2.13 Billion |
| Net Cash Flow | $-588.70 Million |
| Exchange Gains/Losses | $54.60 Million |
| Net Cash Flow From Investing Activities | $-1.43 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Costs And Expenses | $7.70 Billion |
| Net Income/Loss | $1.61 Billion |
| Gross Profit | $7.26 Billion |
| Revenues | $9.61 Billion |
| Operating Expenses | $5.36 Billion |
| Other Operating Expenses | $3.02 Billion |
| Diluted Earnings Per Share | $11.06 |
| Interest Expense, Operating | $261.80 Million |
| Cost Of Revenue | $2.35 Billion |
| Diluted Average Shares | $146.10 Million |
| Operating Income/Loss | $1.91 Billion |
| Benefits Costs and Expenses | $7.70 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $1.62 Billion |
| Income/Loss From Continuing Operations Before Tax | $1.91 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $800000.00 |
| Income/Loss From Continuing Operations After Tax | $1.61 Billion |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Income Tax Expense/Benefit, Deferred | $-27.80 Million |
| Basic Average Shares | $145.50 Million |
| Income Tax Expense/Benefit | $291.70 Million |
| Basic Earnings Per Share | $11.10 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss Attributable To Parent | $1.62 Billion |
| Selling, General, and Administrative Expenses | $2.33 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Non-current Assets | $8.47 Billion |
| Noncurrent Liabilities | $6.53 Billion |
| Intangible Assets | $9.81 Billion |
| Equity | $16.36 Billion |
| Other Current Liabilities | $4.71 Billion |
| Inventory | $2.47 Billion |
| Other Non-current Liabilities | $1.98 Billion |
| Accounts Payable | $422.70 Million |
| Wages | $288.70 Million |
| Assets | $28.31 Billion |
| Liabilities | $11.95 Billion |
| Equity Attributable To Parent | $16.36 Billion |
| Fixed Assets | $3.21 Billion |
| Liabilities And Equity | $28.31 Billion |
| Current Assets | $6.83 Billion |
| Long-term Debt | $4.55 Billion |
| Noncurrent Assets | $21.48 Billion |
| Other Current Assets | $4.36 Billion |
| Current Liabilities | $5.42 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Biogen Inc. Common Stock (BIIB)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.